Developer docs
API playgroundTry for free, no card

Search company profiles

Braidwell

Full company profile

uuid00036pn

Namestring
Braidwell
Legal namestring
Braidwell LP
Websiteurl
braidwell.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Braidwell is a privately held healthcare-focused investment firm, organized as Braidwell LP (Delaware), headquartered in Stamford, Connecticut. Founded in 2022 by Alex Karnal and Brian Kreiter, the firm provides flexible capital and partnership to healthcare companies across all stages of development and all parts of the capital structure, spanning both public and private markets. Its core product is the Braidwell Partners Fund, an AI-centered healthcare hedge fund that posted a 28% gross return in 2025 and managed approximately $3.1 billion in assets at year-end 2025, with $3.5 billion raised in cumulative capital since inception.

The firm is differentiated by an approximately 40-person team that combines molecular biologists, biostatisticians, AI engineers, and portfolio managers, enabling domain-specialized evaluation at the intersection of AI and biology. Braidwell's portfolio spans diagnostics (Guardant Health, GRAIL, Caris Life Sciences), medical devices (Alphatec Holdings, Impulse Dynamics), ophthalmology (Kodiak Sciences), proteomics (Alamar Biosciences), AI-native biotech (Lila Sciences, Proxima), and neuroprotection (Perceive Pharma), with capital deployed across venture rounds, private placements, structured debt, and public equities.

Braidwell generates revenue through management fees and performance allocations on its investment funds, distributed through direct institutional fundraising to qualified LPs including pension funds, endowments, foundations, and family offices. Go-to-market is sales-led and relationship-driven, reinforced by thought leadership via Bloomberg, Reuters, podcast appearances, and active LinkedIn presence from the co-founders. Specific fee economics are not publicly disclosed.

Short descriptiontext

Braidwell is a Stamford, Connecticut-based healthcare hedge fund founded in 2022 that manages approximately $3.1 billion across public and private markets for institutional LPs. Its 40-person team combines molecular biologists, biostatisticians, AI engineers, and portfolio managers to deploy flexible capital into AI-driven biopharmaceutical and healthcare technology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare investment management, biopharmaceutical hedge fund, life sciences venture capital, AI-driven healthcare investing, medical device financing
Industry1 code
PRIMARYFSANACAO
Multi-Sector / Generalist Growth Equity
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Investment Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management
TypeSubscription Recurring
Description

Braidwell generates returns through managing healthcare-focused investment funds, providing flexible capital and thoughtful partnership to companies at all stages of development across public and private markets

braidwell.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Braidwell provides flexible capital and thoughtful partnership to healthcare companies at all stages of development, at all parts of the capital structure, across public and private markets. The firm operates its flagship Braidwell Partners Fund, a healthcare-focused hedge fund managed by an approximately 40-person team that combines molecular biologists, biostatisticians, AI engineers, and portfolio managers to invest in companies developing medicines, materials, and technologies that transform human health.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 28% gross return in 2025
+2 more records
Product overview1 text field

Braidwell is a healthcare-focused investment firm operating as a single unified platform rather than a modular product suite. The core offering is the Braidwell Partners Fund, an AI-focused healthcare hedge fund that manages approximately $3.1 billion in assets. The firm provides flexible capital and partnership services to healthcare companies across all stages of development and all parts of the capital structure, spanning both public and private markets. The firm's approximately 40-person team combines expertise in molecular biology, biostatistics, AI engineering, and portfolio management to identify and build healthcare companies at the intersection of AI and biology.

Product and service2 records
1Braidwell Partners Fund
CategoryHealthcare hedge fund
Description

Flagship healthcare hedge fund of Braidwell, focused on artificial intelligence investments in biopharmaceutical and healthcare technology companies. The fund posted a 28% gross return in 2025 and manages approximately $3.1 billion in assets under management. Available to qualified institutional limited partners.

2Flexible Capital and Partnership Services
CategoryInvestment capital and partnership services
Description

Braidwell's core service offering to healthcare companies: flexible capital and thoughtful partnership across all stages of development, at all parts of the capital structure, across public and private markets, including growth equity, non-dilutive debt, venture rounds, convertibles, and structured financings.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Venture-stage biotech investor with deep science orientation; comparable in research-driven approach but focused on earlier stages than Braidwell's flexible mandate.

TypeDirect peer
Description

Healthcare-focused investment manager with a public/private crossover strategy, often co-investing alongside Braidwell in private biotech rounds.

TypeDirect peer
Description

Healthcare-focused investment firm with a crossover public/private strategy and deep life sciences research capabilities; one of the closest comparables to Braidwell's fund structure.

TypeBroad incumbent
Description

Healthcare-dedicated investment firm where Braidwell CIO Alex Karnal spent 16 years; broader and more established, with public market, private equity, and venture operations.

TypeDirect peer
Description

Healthcare-dedicated investment firm across private equity, public equity, and royalty/credit strategies—comparable in vertical specialization and capital-structure flexibility.

TypeDirect peer
Description

Healthcare-focused crossover fund investing across public and private biotech with a research-driven, science-led approach—directly comparable to Braidwell's AI-augmented, healthcare-specialist model.

TypeDirect peer
Description

Biotech-focused crossover fund making public and private investments in therapeutic companies; directly comparable in mandate and stage flexibility.

8Baker Bros. Advisors
TypeDirect peer
Description

Long-standing healthcare specialist managing both long-only and biotech-focused funds across public equities and venture; a benchmark crossover peer for Braidwell.

9D1 Capital Partners
TypeDirect peer
Description

Large crossover fund with significant healthcare exposure across public and private markets; competes with Braidwell for institutional LP capital and late-stage biotech deals.

10Kynam Capital
TypeEmerging player
Description

Healthcare-focused crossover manager with a public/private mandate similar to Braidwell's, though at an earlier stage of AUM growth.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment40 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Braidwell

Healthcare Investment Managementbraidwell.com

Braidwell is a Stamford, Connecticut-based healthcare hedge fund founded in 2022 that manages approximately $3.1 billion across public and private markets for institutional LPs. Its 40-person team combines molecular biologists, biostatisticians, AI engineers, and portfolio managers to deploy flexible capital into AI-driven biopharmaceutical and healthcare technology companies.

What Braidwell does

Braidwell is a privately held healthcare-focused investment firm, organized as Braidwell LP (Delaware), headquartered in Stamford, Connecticut. Founded in 2022 by Alex Karnal and Brian Kreiter, the firm provides flexible capital and partnership to healthcare companies across all stages of development and all parts of the capital structure, spanning both public and private markets. Its core product is the Braidwell Partners Fund, an AI-centered healthcare hedge fund that posted a 28% gross return in 2025 and managed approximately $3.1 billion in assets at year-end 2025, with $3.5 billion raised in cumulative capital since inception.

The firm is differentiated by an approximately 40-person team that combines molecular biologists, biostatisticians, AI engineers, and portfolio managers, enabling domain-specialized evaluation at the intersection of AI and biology. Braidwell's portfolio spans diagnostics (Guardant Health, GRAIL, Caris Life Sciences), medical devices (Alphatec Holdings, Impulse Dynamics), ophthalmology (Kodiak Sciences), proteomics (Alamar Biosciences), AI-native biotech (Lila Sciences, Proxima), and neuroprotection (Perceive Pharma), with capital deployed across venture rounds, private placements, structured debt, and public equities.

Braidwell generates revenue through management fees and performance allocations on its investment funds, distributed through direct institutional fundraising to qualified LPs including pension funds, endowments, foundations, and family offices. Go-to-market is sales-led and relationship-driven, reinforced by thought leadership via Bloomberg, Reuters, podcast appearances, and active LinkedIn presence from the co-founders. Specific fee economics are not publicly disclosed.

Braidwell firmographics

Firmographics
Name
Braidwell
Legal name
Braidwell LP
Website
https://braidwell.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Braidwell is a Stamford, Connecticut-based healthcare hedge fund founded in 2022 that manages approximately $3.1 billion across public and private markets for institutional LPs. Its 40-person team combines molecular biologists, biostatisticians, AI engineers, and portfolio managers to deploy flexible capital into AI-driven biopharmaceutical and healthcare technology companies.
Ownership category
akta.pro rank

Braidwell industry classification

Industry
Product category
Healthcare Investment Management
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAO
Multi-Sector / Generalist Growth Equity

Keywords

  • Healthcare investment management
  • Biopharmaceutical hedge fund
  • Life sciences venture capital
  • AI-driven healthcare investing
  • Medical device financing

Where Braidwell is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Braidwell business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Investment Management: Braidwell generates returns through managing healthcare-focused investment funds, providing flexible capital and thoughtful partnership to companies at all stages of development across public and private markets

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Braidwell product offering

Product offering

Core offering

Braidwell provides flexible capital and thoughtful partnership to healthcare companies at all stages of development, at all parts of the capital structure, across public and private markets. The firm operates its flagship Braidwell Partners Fund, a healthcare-focused hedge fund managed by an approximately 40-person team that combines molecular biologists, biostatisticians, AI engineers, and portfolio managers to invest in companies developing medicines, materials, and technologies that transform human health.

Product overview

Braidwell is a healthcare-focused investment firm operating as a single unified platform rather than a modular product suite. The core offering is the Braidwell Partners Fund, an AI-focused healthcare hedge fund that manages approximately $3.1 billion in assets. The firm provides flexible capital and partnership services to healthcare companies across all stages of development and all parts of the capital structure, spanning both public and private markets. The firm's approximately 40-person team combines expertise in molecular biology, biostatistics, AI engineering, and portfolio management to identify and build healthcare companies at the intersection of AI and biology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Braidwell Partners Fund Flagship healthcare hedge fund of Braidwell, focused on artificial intelligence investments in biopharmaceutical and healthcare technology companies. The fund posted a 28% gross return in 2025 and manages approximately $3.1 billion in assets under management. Available to qualified institutional limited partners.
  • Flexible Capital and Partnership Services Braidwell's core service offering to healthcare companies: flexible capital and thoughtful partnership across all stages of development, at all parts of the capital structure, across public and private markets, including growth equity, non-dilutive debt, venture rounds, convertibles, and structured financings.

Quantifiable outcome

  • 28% gross return in 2025
  • +2 more outcomes

Companies that use Braidwell

Customer profile

Segments1 record

Ideal customer profiles2 records

Braidwell technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Braidwell partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Braidwell competitors and assessment

Company assessment

Emerging players

  • ARCH Venture Partners: Venture-stage biotech investor with deep science orientation; comparable in research-driven approach but focused on earlier stages than Braidwell's flexible mandate.
  • Kynam Capital: Healthcare-focused crossover manager with a public/private mandate similar to Braidwell's, though at an earlier stage of AUM growth.

Direct peers

  • Cormorant Asset Management: Healthcare-focused investment manager with a public/private crossover strategy, often co-investing alongside Braidwell in private biotech rounds.
  • Perceptive Advisors: Healthcare-focused investment firm with a crossover public/private strategy and deep life sciences research capabilities; one of the closest comparables to Braidwell's fund structure.
  • OrbiMed Advisors: Healthcare-dedicated investment firm across private equity, public equity, and royalty/credit strategies—comparable in vertical specialization and capital-structure flexibility.
  • RA Capital Management: Healthcare-focused crossover fund investing across public and private biotech with a research-driven, science-led approach—directly comparable to Braidwell's AI-augmented, healthcare-specialist model.
  • Boxer Capital: Biotech-focused crossover fund making public and private investments in therapeutic companies; directly comparable in mandate and stage flexibility.
  • Baker Bros. Advisors: Long-standing healthcare specialist managing both long-only and biotech-focused funds across public equities and venture; a benchmark crossover peer for Braidwell.
  • D1 Capital Partners: Large crossover fund with significant healthcare exposure across public and private markets; competes with Braidwell for institutional LP capital and late-stage biotech deals.

Broad incumbents

  • Deerfield Management: Healthcare-dedicated investment firm where Braidwell CIO Alex Karnal spent 16 years; broader and more established, with public market, private equity, and venture operations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Braidwell social profiles

Digital presence

Braidwell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Braidwell leadership team

Management profile

Number of profiles

Profiles2 records

Braidwell funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Braidwell M&A and investment

M&A and investment

M&A

Investments40 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Braidwell

What does Braidwell do?

Braidwell provides flexible capital and thoughtful partnership to healthcare companies at all stages of development, at all parts of the capital structure, across public and private markets. The firm operates its flagship Braidwell Partners Fund, a healthcare-focused hedge fund managed by an approximately 40-person team that combines molecular biologists, biostatisticians, AI engineers, and portfolio managers to invest in companies developing medicines, materials, and technologies that transform human health.

Is Braidwell a public or private company?

Braidwell is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Braidwell founded?

Braidwell was founded in 2022. It employs 11 to 50 people.

Where is Braidwell based?

Braidwell is headquartered in Stamford, United States, in the North America region.

How does Braidwell make money?

One revenue line is on record: investment Management.

Who are Braidwell's main competitors?

Emerging players on record are ARCH Venture Partners and Kynam Capital. Direct peers are Cormorant Asset Management, Perceptive Advisors, OrbiMed Advisors, RA Capital Management, Boxer Capital, Baker Bros. Advisors and D1 Capital Partners. Deerfield Management is listed as a broad incumbent.

Does Braidwell have an API?

No public API is recorded for Braidwell.

What industry is Braidwell in?

Braidwell's product category is Healthcare Investment Management. Its primary akta.pro industry code is FSANACAO, Multi-Sector / Generalist Growth Equity. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coGalvanize raises $130M Series D for pulsed-field expansion | Dealroom NewsGalvanize Therapeutics closed a $130 million Series D led by HealthQuest Capital, with participation from Olympus Innovation Ventures and Braidwell LP. The funding follows an oversubscribed Series C and will support commercial expansion of its Aliya EX generator, clinical evidence, and next-generation PEF platforms. The company has surpassed 4,000 procedures and enrolled over 300 patients in its PROPEL registry.Ticker ReportBraidwell LP Purchases New Holdings in Immunic, Inc. $IMUXBraidwell LP acquired a new position in Immunic, Inc. during Q2, purchasing 645,010 shares valued at approximately $9.9 million. The stock opened at $14.24, and analysts have an average "Buy" rating with a consensus price target of $47.25.Ticker ReportCelldex Therapeutics, Inc. $CLDX Shares Sold by Braidwell LPBraidwell LP trimmed its Celldex Therapeutics stake by 67.8% in Q2, selling 919,436 shares and holding 436,646 shares worth $16.2 million. Analysts have set a consensus price target of $56.08, with several firms raising targets. Celldex reported a loss of $0.94 per share for the quarter.Markets DailyBraidwell LP Takes Position in GH Research PLC $GHRSBraidwell LP acquired a new stake in GH Research PLC during Q2, purchasing 207,240 shares valued at about $5.57 million. Other institutional investors also adjusted positions, with hedge funds holding 56.90% of the company's stock. The stock opened at $28.07, and analysts have a consensus 'Moderate Buy' rating with an average target price of $45.00.Markets DailyBraidwell LP Cuts Stake in Kiniksa Pharmaceuticals International, plc $KNSABraidwell LP cut its stake in Kiniksa Pharmaceuticals International by 32.5% in Q2, selling 88,700 shares and leaving with 183,822 shares valued at $11.755 million. Other institutional investors, including Qube Research and Rubric Capital, increased their positions, while insiders sold shares. Analysts rate the stock a Moderate Buy with an average target of $87.38.FinSMEsLila Sciences Raises $350M in Series A FundingLila Sciences raised $350M in Series A funding co-led by Braidwell and Collective Global. The company will use the funds to accelerate its automated AI Science Factories, expand its software platform, and scale its international engineering team. It has raised $550M in total funding.247wallstBiotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public HealthAlex Karnal, co-founder and CIO of life sciences investment firm Braidwell, declared 2025 the most exciting year in his career on the Invest Like the Best podcast, arguing GLP-1 medicines represent a potential "trillion-dollar revolution" in public health with annual revenues exceeding $100 billion. Eli Lilly generated $36.5 billion in combined GLP-1 drug sales in 2025 (56% of revenues), with its stock gaining 407% over five years, while competitor Novo Nordisk faces headwinds including a CagriSema clinical trial setback showing 23% weight loss versus Lilly's tirzepatide at 25.5%, a nearly 20% year-to-date stock decline, and patent expiration in India in March 2026. Analysts at Jefferies and Goldman Sachs have revised weight-loss market forecasts downward due to steeper price erosion, Medicare GLP-1 obesity coverage remains unresolved, and major insurers including CVS have opted out, creating near-term asymmetric risks despite the long-term structural thesis.HedgeweekBraidwell’s AI-focused healthcare hedge fund up 28% in 2025Braidwell, a Stamford, Connecticut-based healthcare hedge fund focused on artificial intelligence, posted a 28% gross return in 2025, with its flagship Braidwell Partners Fund managing approximately $3.1 billion in assets. The firm, founded in 2022 by former Deerfield Management executive Alex Karnal and former Bridgewater Associates COO Brian Kreiter, said it plans to expand investments in AI-driven biopharmaceutical companies as opportunities in the sector continue to grow. Key contributors to gains included healthcare technology and diagnostics companies Guardant Health, Alphatec Holdings, and Caris Life Sciences, as well as early-stage ventures Lila Sciences and Proxima.ReutersBraidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last yearBraidwell, an investment firm launched in 2022 by former Deerfield executive Alex Karnal and former Bridgewater COO Brian Kreiter, posted a 28% gross return in 2025 for its flagship fund, with assets under management of approximately $3.1 billion at the end of the December quarter. The Stamford, Connecticut-based firm, which has raised $3.5 billion since inception and built a portfolio including Guardant Health, Alphatec, and Caris Life Sciences, is planning to increase its focus on AI-focused biopharmaceutical companies in 2026. Braidwell's roughly 40-person team combines molecular biologists, biostatisticians, AI engineers, and portfolio managers to identify and build healthcare companies at the intersection of AI and biology.YahooInside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts AheadConnecticut-based investment firm Braidwell LP disclosed a new position in Kodiak Sciences, acquiring 2,072,788 shares valued at approximately $57.96 million during Q4 2025, according to an SEC filing dated February 17, 2026. The position represents 1.85% of Braidwell's 13F reportable assets under management. Kodiak Sciences is a clinical-stage biotech company developing treatments for retinal diseases, with shares up 340% over the past year and three Phase 3 topline readouts expected across 2026.